Sang Wook Jin1, Ji Sang Min2. 1. Department of Ophthalmology, Dong-A University Medical Center, #26 Daesingongwon-ro, Seo-gu, Busan, 602-715, Republic of Korea. jinnham@hanmail.net. 2. Department of Ophthalmology, Dong-A University Medical Center, #26 Daesingongwon-ro, Seo-gu, Busan, 602-715, Republic of Korea.
Abstract
PURPOSE: To investigate the effects of diquafosol on intraocular pressure (IOP) and dry eye symptoms in glaucoma patients with dry eye syndrome (DES). METHODS: This study evaluated a total of 138 glaucoma patients with DES who were treated with diquafosol ophthalmic solution (DIQUAS(®)). Before treatment and 1, 4, 12, 36, and 52 weeks after treatment, IOP, ocular surface disease index (OSDI), tear film break-up time (BUT), Schirmer I test scores, fluorescein staining, conjunctival impression cytology, and adverse drug reactions were evaluated. RESULTS: Throughout the treatment period, the mean IOP for all the patients remained stable after treatment with diquafosol (15.4 ± 2.8 mmHg at baseline and 16.0 ± 2.8 mmHg at 52 weeks). The mean OSDI score improved significantly at 4, 12, and 52 weeks after diquafosol treatment. The BUT and Schirmer I test scores were significantly increased after diquafosol treatment. The Oxford scheme score was significantly decreased at 1, 4, 12, 36, and 52 weeks after diquafosol treatment. A significant improvement in goblet cell density was observed after 4 weeks of treatment with diquafosol. Adverse drug reactions were reported in 22 (15.9 %) patients. There were no serious adverse drug reactions. CONCLUSIONS: Diquafosol was effective in improving objective and subjective symptoms and maintained a stable IOP in glaucoma patients with DES. Therefore, the addition of diquafosol treatment in glaucoma patients with DES or ocular surface side effects using anti-glaucoma medication may be beneficial.
PURPOSE: To investigate the effects of diquafosol on intraocular pressure (IOP) and dry eye symptoms in glaucomapatients with dry eye syndrome (DES). METHODS: This study evaluated a total of 138 glaucomapatients with DES who were treated with diquafosol ophthalmic solution (DIQUAS(®)). Before treatment and 1, 4, 12, 36, and 52 weeks after treatment, IOP, ocular surface disease index (OSDI), tear film break-up time (BUT), Schirmer I test scores, fluorescein staining, conjunctival impression cytology, and adverse drug reactions were evaluated. RESULTS: Throughout the treatment period, the mean IOP for all the patients remained stable after treatment with diquafosol (15.4 ± 2.8 mmHg at baseline and 16.0 ± 2.8 mmHg at 52 weeks). The mean OSDI score improved significantly at 4, 12, and 52 weeks after diquafosol treatment. The BUT and Schirmer I test scores were significantly increased after diquafosol treatment. The Oxford scheme score was significantly decreased at 1, 4, 12, 36, and 52 weeks after diquafosol treatment. A significant improvement in goblet cell density was observed after 4 weeks of treatment with diquafosol. Adverse drug reactions were reported in 22 (15.9 %) patients. There were no serious adverse drug reactions. CONCLUSIONS:Diquafosol was effective in improving objective and subjective symptoms and maintained a stable IOP in glaucomapatients with DES. Therefore, the addition of diquafosol treatment in glaucomapatients with DES or ocular surface side effects using anti-glaucoma medication may be beneficial.
Authors: Ashley Behrens; John J Doyle; Lee Stern; Roy S Chuck; Peter J McDonnell; Dimitri T Azar; Harminder S Dua; Milton Hom; Paul M Karpecki; Peter R Laibson; Michael A Lemp; David M Meisler; Juan Murube Del Castillo; Terrence P O'Brien; Stephen C Pflugfelder; Maurizio Rolando; Oliver D Schein; Berthold Seitz; Scheffer C Tseng; Gysbert van Setten; Steven E Wilson; Samuel C Yiu Journal: Cornea Date: 2006-09 Impact factor: 2.651
Authors: Kimberly L Miller; John G Walt; David R Mink; Sacha Satram-Hoang; Steven E Wilson; Henry D Perry; Penny A Asbell; Stephen C Pflugfelder Journal: Arch Ophthalmol Date: 2010-01
Authors: Jose Maria Martinez-de-la-Casa; Carlos Oribio-Quinto; Almudena Milans-Del-Bosch; Pilar Perez-Garcia; Laura Morales-Fernandez; Javier Garcia-Bella; Jose Manuel Benitez-Del-Castillo; Julian Garcia-Feijoo; David P Piñero Journal: Eye Vis (Lond) Date: 2022-04-01